Attention Guest: Please make sure that you are using a unique password to login to MESO. If you have used your MESO password on another website, change it immediately. You should NEVER share the same login credentials on multiple websites.

PROLOR Biotech Inc (NYSEMKT:PBTH)

Discussion in 'Men's Economics' started by Michael Scally MD, Jun 4, 2013.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    PROLOR Biotech Inc (NYSEMKT:pBTH)
    PROLOR Biotech


    PROLOR Biotech Initiates Pivotal Phase III Trial Of Its Longer-Acting Version Of Human Growth Hormone
    PROLOR Biotech Initiates Pivotal Phase III Trial Of Its Longer-Acting Version Of Human Growth Hormone - Yahoo! Finance

    PROLOR Biotech, Inc. (NYSE Mkt: PBTH), today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone (hGH), in growth hormone deficient adults. PROLOR is developing hGH-CTP to provide growth hormone deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly injections, rather than the daily injections required by current hGH therapy. The initiation of the Phase III clinical trial follows a set of successful Phase II trials showing that hGH-CTP has the potential to be effective when injected once weekly. In these studies, hGH-CTP was shown to be well tolerated and safe, and it met all clinical endpoints.
     
  2. Latebgnr

    Latebgnr Junior Member

    Great article, thank you!!